About 689,084 shares traded. Company insiders own 15.26% of the company’s stock. It has underperformed by 1.24% the S&P500. (JUNO) stake by 33.1% reported in 2016Q4 SEC filing. Canada Pension Plan Investment Board holds 0% in Juno Therapeutics Inc (NASDAQ:JUNO) or 44,700 shares. For the week, the stock is performing -2.53%. The Sii Investments Inc holds 68,870 shares with $5.95M value, down from 76,429 last quarter. Juno Therapeutics Inc. now has $3.82 billion valuation.
At the time of writing, the stock was trading at $35.98. Director Richard Klausner sold 12,000 shares at an average price of $30.34 on Monday the 7th. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 39.85% since August 28, 2016 and is downtrending.
Investors sentiment decreased to 0.98 in 2016 Q4. Its up 0.22, from 1.11 in 2016Q3. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the stock in a transaction that occurred on Thursday, July 13th. Reynders Mcveigh Llc, a Massachusetts-based fund reported 4,743 shares. Profund Advsrs Limited Liability Corp has 33,674 shares. Evercore Wealth Management Lc has 0.02% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 22,062 shares. 68,993 are held by Horan Cap Mngmt. Great West Life Assurance Company Can holds 4,718 shares or 0% of its portfolio. Psagot Invest House Ltd holds 36 shares. When investing in a volatile security, the risk of success is increased just as much as the risk of failure. 38,521 were reported by Baring Asset Mgmt Limited. It was reported on Aug, 28 by Barchart.com. The company’s revenue was down 22.8% on a year-over-year basis. Technical analysts have little regard for the value of a company. The rating was maintained by Jefferies on Tuesday, May 30 with “Buy”. As per Tuesday, June 27, the company rating was downgraded by Susquehanna. The firm has “Buy” rating by Maxim Group given on Friday, August 5. The company have shares float of 80.51 million. The firm earned “Underperform” rating on Thursday, September 15 by CLSA. The firm has “Outperform” rating given on Thursday, June 2 by Raymond James. The company was initiated on Friday, September 11 by Bernstein. Richard Klausner, Director reported the sale of 24,000 shares of (JUNO). Preete Kerry J sold $1.33 million worth of stock. Development sold $262,500 worth of shares at an average price of $30.00 on Tue the 27th. Including today’s unusual volume, Juno Therapeutics, Inc.’s stock is performing at 63.02% on the year. Therefore 40% are positive. On average, analysts predict that Juno Therapeutics, Inc. will post ($3.13) earnings per share for the current fiscal year. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) has “Neutral” rating given on Wednesday, November 18 by Goldman Sachs. Juno Therapeutics has a 52 week low of $17.52 and a 52 week high of $37.50. On Friday, July 8 the stock rating was downgraded by JP Morgan to “Neutral”. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Outperform” rating by Wells Fargo on Wednesday, February 22. As per Thursday, February 25, the company rating was initiated by Citigroup. Finally, Vetr upgraded Juno Therapeutics to a “buy” rating in a research report on Tuesday, May 23rd.
Investors sentiment decreased to 1.04 in 2016 Q4. Its up 0.22, from 1.11 in 2016Q3. BB Biotech AG increased its stake in shares of Juno Therapeutics by 16.8% in the first quarter. 23 funds opened positions while 50 raised stakes. California Employees Retirement reported 74,300 shares. Rhumbline Advisers holds 0% or 65,633 shares. Ameriprise Inc reported 358,995 shares stake. QS Investors LLC purchased a new position in Juno Therapeutics during the second quarter worth approximately $135,000. With 1.31M avg volume, 12 days are for Juno Therapeutics Incorporated (NASDAQ:JUNO)’s short sellers to cover JUNO’s short positions. Tci Wealth owns 20 shares or 0% of their USA portfolio. 13,282 were accumulated by Blackrock.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.